share_log

金斯瑞生物科技：海外監管公告: 上市附屬公司傳奇生物科技股份有限公司截至二零二三年十二月三十一日止第四季度及全年的未經審核財務業績

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND THE YEAR ENDED 31 DECEMBER 2023 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

香港交易所 ·  Mar 11 08:08
Summary by Moomoo AI
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）旗下非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」）於2024年3月11日公佈了截至2023年12月31日止第四季度及全年的未經審核財務業績。傳奇生物在美國納斯達克全球精選市場上市，並向美國證券交易委員會提交了6-K表格。傳奇生物2023年第四季度淨貿易銷售額約為1.59億美元，全年約為5億美元。公司亦更新了其候選藥物管線，並獲得諾華製藥股份公司1億美元的預付款。截至2023年底，傳奇生物擁有約13億美元的現金及現金等價物、存款和短期投資，預計資金將支持至2025年底。傳奇生物首席執行官黃穎博士表示，CARVYKTI®的商業化成功，以及與強生的戰略合作，為公司未來增長奠定了基礎。傳奇生物將於美國東部時間今日上午8時舉行季度業績電話會議，並進行網路直播。
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）旗下非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」）於2024年3月11日公佈了截至2023年12月31日止第四季度及全年的未經審核財務業績。傳奇生物在美國納斯達克全球精選市場上市，並向美國證券交易委員會提交了6-K表格。傳奇生物2023年第四季度淨貿易銷售額約為1.59億美元，全年約為5億美元。公司亦更新了其候選藥物管線，並獲得諾華製藥股份公司1億美元的預付款。截至2023年底，傳奇生物擁有約13億美元的現金及現金等價物、存款和短期投資，預計資金將支持至2025年底。傳奇生物首席執行官黃穎博士表示，CARVYKTI®的商業化成功，以及與強生的戰略合作，為公司未來增長奠定了基礎。傳奇生物將於美國東部時間今日上午8時舉行季度業績電話會議，並進行網路直播。
Legend Biotechnology Co., Ltd. (“Legendary Biotech”), a non-wholly owned subsidiary of Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”), announced on March 11, 2024 its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Legendary Bio is listed on the U.S. Nasdaq Global Select Market and filed Form 6-K with the U.S. Securities and Exchange Commission. Legendary Bio's net trade sales for the fourth quarter of 2023 were approximately $1.59 million, compared with approximately $5 million for the full year. The company also updated its candidate drug pipeline and received an upfront payment of $1 million from Novara Pharmaceuticals. As of the end of 2023, Legendary Creatures has approximately $13 billion in cash and cash equivalents, deposits and short-term investments, which is...Show More
Legend Biotechnology Co., Ltd. (“Legendary Biotech”), a non-wholly owned subsidiary of Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”), announced on March 11, 2024 its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Legendary Bio is listed on the U.S. Nasdaq Global Select Market and filed Form 6-K with the U.S. Securities and Exchange Commission. Legendary Bio's net trade sales for the fourth quarter of 2023 were approximately $1.59 million, compared with approximately $5 million for the full year. The company also updated its candidate drug pipeline and received an upfront payment of $1 million from Novara Pharmaceuticals. As of the end of 2023, Legendary Creatures has approximately $13 billion in cash and cash equivalents, deposits and short-term investments, which is expected to be supported by the end of 2025. The success of the commercialization of CARVYKTI®, as well as the strategic partnership with Johnson, lays the foundation for the company's future growth, Dr. Wong Wing, CEO of Legendary Bios. Legendary Creatures will hold a quarterly results teleconference at 8:00 AM ET today with a live webcast.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more